On March 8, 2022 Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, reported that it will present four posters at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting to be held April 8 to 13, 2022 (Press release, Nkarta, MAR 8, 2022, View Source [SID1234609673]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstracts are now available on the AACR (Free AACR Whitepaper) website, www.aacr.org. Posters will be made available electronically on April 8, 2022 at 1:00 p.m. ET on the AACR (Free AACR Whitepaper) e-poster website.

Presented jointly with CRISPR Therapeutics:

Title: CBLB, CISH and CD70 multiplexed gene knockout with CRISPR/Cas9 enhances cytotoxicity of CD70-CAR NK cells and provides greater resistance to TGF-β for cancer immunotherapy
Session Category: Immunology
Session Title: Preclinical Immunotherapy
Abstract Number: 5512

Nkarta presentations:

Title: Surveying surface antigen expression in multiple myeloma preclinical models
Session Category: Tumor Biology
Session Title: Nonclinical Models of Cancer
Abstract Number: 6004

Title: Development of multiomics approaches to evaluate NKG2D ligand dynamics and anti-tumor immune responses during CAR-NK treatment
Session Category: Clinical Research Excluding Trials
Session Title: Immuno-oncology
Abstract Number: 5187

Title: Immune masking strategies to extend the pharmacokinetics of allogeneic cell therapies
Session Category: Immunology
Session Title: Preclinical Immunotherapy
Abstract Number: 5511

On March 8, 2022 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that it will present an e-poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and online (Press release, CRISPR Therapeutics, MAR 8, 2022, View Source [SID1234609672]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: CBLB, CISH and CD70 multiplexed gene knockout with CRISPR/Cas9 enhances cytotoxicity of CD70-CAR NK cells and provides greater resistance to TGF-β for cancer immunotherapy
Session Title: Preclinical Immunotherapy
Session Category: Immunology
Abstract Number: 5512, e-poster
Date and Time: Friday, April 8, 2022, 1:00 p.m. via the AACR (Free AACR Whitepaper) website, www.aacr.org

On March 8, 2022 Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, reported a poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, being held virtually and in New Orleans, Louisiana from April 8-13, 2022 (Press release, Vincerx Pharma, MAR 8, 2022, View Source [SID1234609671]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster presentation details:
Poster Title: VIP152, a selective CDK9 inhibitor, demonstrates sensitivity in gynecologic cell lines that are cisplatin sensitive or resistant and delivers in vivo antitumor efficacy
Abstract Number: 4939
Presenter: Melanie Frigault, PhD
Session Type: In-Person and e-Poster Presentation
Session Title: Mechanisms of Drug Action 2
Session Time: April 11, 2022 at 1:30PM CT
Location: Poster Section 25
A copy of the presentation materials can be accessed on the Investors section of the Company’s website at www.vincerx.com once the presentation has concluded.

On March 8, 2022 Theratechnologies Inc. ("Theratechnologies" or "the Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported that three poster abstracts have been accepted for presentation at the 2022 Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) to be held April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana (Press release, Theratechnologies, MAR 8, 2022, View Source [SID1234609670]). The Company will present new in vivo TH1902 preclinical data demonstrating tumor growth inhibition of human cancer stem-like cells (CD133+) in both triple-negative breast and ovarian cancers. Theratechnologies will also present new in vivo data on anti-cancer efficacy of TH1902 against ovarian and endometrial cancers, in addition to the inhibitory effect of TH1902 on subcutaneous melanoma xenografts and formation of lung metastases in a syngeneic mouse model.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster abstract details and presentation sessions are as follows:
(All posters will go live on AACR (Free AACR Whitepaper)’s website on Friday, April 8 at 1 p.m. ET)

Title: "TH1902, a SORT1 docetaxel peptide-drug conjugate, inhibits tumor growth of human cancer stem-like cells (CD133+) from both triple-negative breast cancers and ovarian cancers"
Presentation Type: In person and e-Poster
Session Date and Time: April 11, 1:30 PM – 5:00 PM (On-demand e-poster display)

Title: "Anti-cancer efficacy of TH1902, a SORT1 docetaxel peptide-drug conjugate, against ovarian and endometrial cancers xenografts alone or in combination with carboplatin"
Presentation Type: In person and e-Poster
Session Date and Time: April 11, 9:00 AM – 12:30 PM (On-demand e-poster display)

Title: "The peptide-drug conjugate TH1902 inhibits growth of subcutaneous melanoma xenografts and formation of lung metastases in a syngeneic mouse model"
Presentation Type: In person and e-Poster
Session Date and Time: April 11, 9:00 AM – 12:30 PM (On-demand e-poster display)

All of the above Abstracts will be made publicly available today, March 8, 2022, from 4:30 p.m. (EST) View Source!/10517.

On March 8, 2022 Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, reported that it will present new preclinical data on its CDK12 inhibitor program at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana (Press release, Syros Pharmaceuticals, MAR 8, 2022, View Source [SID1234609668]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The online-only e-poster will include data that show Syros’ orally available, selective CDK12 inhibitor has potent single agent activity in vitro and in vivo in multiple cancer models as well as enhanced antitumor effect in combination with DNA damaging agents. These data support Syros’ plans to nominate a development candidate from its CDK12 inhibitor program in the second half of 2022.

Details of the e-poster presentation are as follows:

Presentation Title: An oral and selective CDK12 inhibitor demonstrates robust anti-tumor activity
Session Title: Molecular Targets
Session Category: Experimental and Molecular Therapeutics
Abstract Number: 5393

The abstract is now available on the AACR (Free AACR Whitepaper) conference website: View Source The e-poster will become available on the AACR (Free AACR Whitepaper) conference website at 1:00 p.m. ET on Friday, April 8th.